Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of AR-12 for the treatment of the COVID 19 Infection

Next Previous
X
Search
Trial Profile

A clinical study of AR-12 for the treatment of the COVID 19 Infection

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 15 Oct 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AR 12 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions

    • Most Recent Events

    • 15 Oct 2020 New trial record
    • 21 Sep 2020 According to a VCU Massey Cancer Center media release, the company expects to initiate this study in early 2021. However, the are may milestone to complete before the initiation of the study. The team must develop the clinical trial protocol, receive approval from the FDA to test AR-12 on COVID-19 patients and manufacture enough of the drug for the trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top